News | 06 January 2023
Chindex Medical acquires 10 ViewRay MRIdian Systems for advanced cancer treatment
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
Purchase agreement with ViewRay will make state-of-the art precision radiation therapy available in China
Chyawanprash Special will be available at all Jan Aushadhi Kendras
Seeks partnership between government and private medical colleges for providing superior medical education
Diclofenac epolamine topical system 1.3% offers patients a non-opioid topical treatment
Biocytogen will provide a license to Hansoh Pharma for their selected fully human antibody molecules
The PharmaEssentia Innovation Research Center (PIRC) will advance the company’s diverse pipeline and research footprint in the U.S., driving job creation
The collaboration with IIT Kanpur will build on this foundation and expand the domain of research and development in healthcare technology
The unit will have installed manufacturing capacity of over 15 million vials annually that includes lyophilized vials, all in the anti-cancer segment
It ensures sufficient serum estradiol levels to alleviate menopausal symptoms
BDRs journey for the treatment of Prostate Cancer started with Abiratarone Acetate, then Leuprolide Acetate followed by Enzalutamide and, then Degarelix and Triptorelin.
The strategic acquirer maintains a nationwide presence in the LTC pharmacy space
To create leading company developing medicines targeting metalloenzymes
Kyfora Bio will focus on the synthesis of cationic polymers, lipids, and other materials used in nucleic acid delivery for cell and gene therapies.
The company is one of the most profitable companies manufacturing speciality chemicals in India
Krishna Institute of Medical Sciences to consider raising Rs. 300 crores
Cipla and Ethris partner for the development of mRNA-based therapies
All claims against the company in the litigation have now been dismissed.
There have been reports from Uzbekistan concerning contaminated cough syrup Dok1 Max made by Indian company Marion Biotech, Noida, Uttar Pradesh
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
Subscribe To Our Newsletter & Stay Updated
